Delivery Order SPE2DB22D1103-SPE2DB24FTFY9
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is for the delivery of MENQUADFI VIAL 0.5ML, with a potential value of $2,107.44 and a completion date of January 29, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a potential value of...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the pharmaceutical product MENQUADFI VIAL 0.5ML. The contract has a ceiling value of $5,028.10 and a period of performance through February 6, 2023. This award is associated with a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp, which has a potential value of $999,999,999.00 and...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $3,512.40 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide MENQUADFI VIAL 0.5ML pharmaceutical products. The contract has a completion date of January 29, 2024. Amerisourcebergen Drug Corp is the prime contractor and does not have any major subcontractors identified. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4564017415 MENQUADFI VIAL 0.5ML. The contract has a ceiling value of $10,537.20 and a period of performance through March 21, 2024. Amerisourcebergen Drug Corp is also the prime contractor on a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded by DLA to deliver...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply MENQUADFI VIAL 0.5ML pharmaceutical products. The contract has a potential value of $5,654.52 and a performance period through February 23, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor and holds an indefinite delivery contract (IDC) with DLA valued at up to...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of pharmaceutical supplies and medical materials such as the "MENQUADFI VIAL 0.5ML" product. The contract has a potential value of $1,756.20 and a completion date of February 22, 2024. Amerisourcebergen Drug Corp holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of MENQUADFI VIAL 0.5ML pharmaceutical products. The $1,053.72 contract has a performance period through February 1, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp, as the prime contractor, will deliver these products to support military treatment programs and...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $1,404.96 contract is for the supply of MENQUADFI VIAL 0.5ML, a pharmaceutical product, with a completion date of February 1, 2024. This delivery order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,756.20 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division. The contract, which does not have a set-aside designation, is for the supply of 4564736964 ! MENQUADFI VIAL 0.5ML medical products. This delivery order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. Under this IDC,...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division to provide 4565005303 MENQUADFI VIAL 0.5ML pharmaceutical products. The firm-fixed-price contract has a ceiling value of $79,447.18 and an ultimate completion date of June 27, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. Under this...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB24FTFY9Delivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of MENQUADFI VIAL 0.5ML pharmaceuticals. The contract has a potential value of $1,756.20 and a completion date of March 5, 2024. This delivery order is issued under a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA that has a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceuticals and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. No set-aside designation was used for this award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Loading... | ||||